Two Sigma Advisers
ITRM

Two Sigma Advisers’s Iterum Therapeutics ITRM Stock Holding History

Two Sigma Advisers’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-953
Closed -$6K – 2810
2021
Q4 		$6K Sell
953
-34
-3% -$263 ﹤0.01% 2584
2021
Q3 		$8K Buy
+987
New +$12.2K ﹤0.01% 2416
2021
Q2 		– Sell
-13,253
Closed -$280K – 2565
2021
Q1 		$280K Buy
+13,253
New +$316K ﹤0.01% 2245

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Advisers's ITRM Position: Q1 2022 in Review

Two Sigma Advisers sold out of Iterum Therapeutics (ITRM) in Q1 2022, closing a stake of 953 shares — an estimated $6K sold.

Two Sigma Advisers first reported a position in ITRM in Q1 2021 and held it in 3 quarters. The position peaked at $280K in Q1 2021. 41 funds tracked by Wall St. Rank hold ITRM as of Q1 2022.

  • Two Sigma Advisers reported no remaining Iterum Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 953 Iterum Therapeutics shares in Q1 2022, an estimated $6K.
  • Two Sigma Advisers first reported a position in Iterum Therapeutics in Q1 2021 and held it in 3 quarters.
  • Two Sigma Advisers's Iterum Therapeutics position peaked at $280K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2022.

Based on Two Sigma Advisers's 13F filing for Q1 2022, filed 16 May 2022.